Pancreatic cancer: Stroma and its current and emerging targeted therapies
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …
Targeting pancreatic stellate cells in cancer
Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …
[HTML][HTML] Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
Normalization of the tumor microenvironment by selectively targeting components of the
tumor extracellular matrix has been recently proposed to have the potential to decompress …
tumor extracellular matrix has been recently proposed to have the potential to decompress …
The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives
Y Wu, C Zhang, K Jiang, J Werner, AV Bazhin… - Frontiers in …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …
[HTML][HTML] Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer
P Ramakrishnan, WM Loh, SCB Gopinath… - … Pharmaceutica Sinica B, 2020 - Elsevier
Activated pancreatic stellate cells (PSCs) have been widely accepted as a key precursor of
excessive pancreatic fibrosis, which is a crucial hallmark of chronic pancreatitis (CP) and its …
excessive pancreatic fibrosis, which is a crucial hallmark of chronic pancreatitis (CP) and its …
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor …
Transforming growth factor-β (TGF-β) plays a critical role in regulating cell growth and
differentiation. Epithelial to mesenchymal transition (EMT) induced by TGF-β promotes …
differentiation. Epithelial to mesenchymal transition (EMT) induced by TGF-β promotes …
The pancreatic cancer microenvironment: A true double agent
LG Melstrom, MD Salazar… - Journal of surgical …, 2017 - Wiley Online Library
The tumor microenvironment in pancreatic cancer is a complex balance of pro‐and anti‐
tumor components. The dense desmoplasia consists of immune cells, extracellular matrix …
tumor components. The dense desmoplasia consists of immune cells, extracellular matrix …
[HTML][HTML] Experimental models of pancreatic cancer desmoplasia
Desmoplasia is a fibro-inflammatory process and a well-established feature of pancreatic
cancer. A key contributor to pancreatic cancer desmoplasia is the pancreatic stellate cell …
cancer. A key contributor to pancreatic cancer desmoplasia is the pancreatic stellate cell …
[HTML][HTML] Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
Background Currently, several antibody (Ab)-based therapies have shown excellent
therapeutic effects in the clinic. Nonetheless, Ab penetration into tumor tissues is limited due …
therapeutic effects in the clinic. Nonetheless, Ab penetration into tumor tissues is limited due …
Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine re-programs the tumor microenvironment and confers enhanced tumor control
DCA Quixabeira, S Zafar, JM Santos… - Frontiers in …, 2021 - frontiersin.org
The notion of developing variants of the classic interleukin 2 (IL-2) cytokine has emerged
from the limitations observed with the systemic use of human IL-2 in the clinic: severe …
from the limitations observed with the systemic use of human IL-2 in the clinic: severe …